Physician profile
Fatta B Nahab
NPI 1942291729
$5,409.45
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,390 · 2021: $19.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $4,502.85 | 2019 | |
| Abbott Laboratories | $182.76 | 2019 | |
| Acadia Pharmaceuticals INC | $170.98 | 2019 | |
| Abbvie INC. | $141.68 | 2019 | |
| Merz North America, INC. | $136.26 | 2019 | |
| Acorda Therapeutics, INC | $50.21 | 2019 | |
| Medtronic USA, INC. | $45.91 | 2019 | |
| Lundbeck LLC | $44.60 | 2019 | |
| Adamas Pharmaceuticals, INC. | $40.59 | 2019 | |
| Boston Scientific Corporation | $37.50 | 2019 | |
| Neurocrine Biosciences, INC. | $21.19 | 2019 | |
| Sunovion Pharmaceuticals INC. | $19.51 | 2021 | |
| Allergan, INC. | $15.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatta Nahab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.